nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—CYP3A4—Topotecan—lung cancer	0.0219	0.142	CbGbCtD
Orlistat—CYP3A4—Gefitinib—lung cancer	0.02	0.13	CbGbCtD
Orlistat—CYP3A4—Teniposide—lung cancer	0.0194	0.126	CbGbCtD
Orlistat—DAGLB—mammary gland—lung cancer	0.0178	0.103	CbGeAlD
Orlistat—CYP3A4—Vinorelbine—lung cancer	0.0154	0.1	CbGbCtD
Orlistat—ABHD12—mammary gland—lung cancer	0.0126	0.0729	CbGeAlD
Orlistat—CYP3A4—Crizotinib—lung cancer	0.0123	0.0796	CbGbCtD
Orlistat—CYP3A4—Erlotinib—lung cancer	0.0118	0.0768	CbGbCtD
Orlistat—CYP3A4—Paclitaxel—lung cancer	0.0108	0.0703	CbGbCtD
Orlistat—CYP3A4—Irinotecan—lung cancer	0.0107	0.0693	CbGbCtD
Orlistat—FASN—mammary gland—lung cancer	0.0106	0.0611	CbGeAlD
Orlistat—DAGLB—bronchus—lung cancer	0.00977	0.0563	CbGeAlD
Orlistat—CYP3A4—Vinblastine—lung cancer	0.0095	0.0617	CbGbCtD
Orlistat—CYP3A4—Etoposide—lung cancer	0.00856	0.0555	CbGbCtD
Orlistat—PNLIP—respiratory system—lung cancer	0.00843	0.0486	CbGeAlD
Orlistat—CYP3A4—Docetaxel—lung cancer	0.00783	0.0508	CbGbCtD
Orlistat—ABHD16A—bronchus—lung cancer	0.0074	0.0426	CbGeAlD
Orlistat—ABHD12—bronchus—lung cancer	0.00694	0.04	CbGeAlD
Orlistat—ABHD16A—trachea—lung cancer	0.00665	0.0383	CbGeAlD
Orlistat—DAGLB—lung—lung cancer	0.0063	0.0363	CbGeAlD
Orlistat—ABHD12—trachea—lung cancer	0.00623	0.0359	CbGeAlD
Orlistat—ABHD12—cardiac atrium—lung cancer	0.00585	0.0337	CbGeAlD
Orlistat—CYP3A4—Doxorubicin—lung cancer	0.00584	0.0379	CbGbCtD
Orlistat—FASN—bronchus—lung cancer	0.00582	0.0335	CbGeAlD
Orlistat—PLA2G7—bone marrow—lung cancer	0.00562	0.0324	CbGeAlD
Orlistat—ABHD16A—bone marrow—lung cancer	0.00527	0.0304	CbGeAlD
Orlistat—FASN—trachea—lung cancer	0.00523	0.0301	CbGeAlD
Orlistat—PLA2G7—lung—lung cancer	0.00509	0.0293	CbGeAlD
Orlistat—ABHD16A—lung—lung cancer	0.00478	0.0275	CbGeAlD
Orlistat—ABHD12—lung—lung cancer	0.00448	0.0258	CbGeAlD
Orlistat—PNLIP—lung—lung cancer	0.00448	0.0258	CbGeAlD
Orlistat—DAGLB—lymph node—lung cancer	0.00431	0.0248	CbGeAlD
Orlistat—FASN—Irinotecan—Topotecan—lung cancer	0.0038	0.354	CbGdCrCtD
Orlistat—FASN—lung—lung cancer	0.00376	0.0216	CbGeAlD
Orlistat—PLA2G7—lymph node—lung cancer	0.00348	0.0201	CbGeAlD
Orlistat—PLA2G4A—respiratory system—lung cancer	0.0034	0.0196	CbGeAlD
Orlistat—ABHD16A—lymph node—lung cancer	0.00327	0.0188	CbGeAlD
Orlistat—PLA2G4A—Raltitrexed—Pemetrexed—lung cancer	0.00321	0.299	CbGdCrCtD
Orlistat—ABHD12—lymph node—lung cancer	0.00306	0.0176	CbGeAlD
Orlistat—PLA2G4A—bronchus—lung cancer	0.0028	0.0161	CbGeAlD
Orlistat—FASN—lymph node—lung cancer	0.00257	0.0148	CbGeAlD
Orlistat—PLA2G4A—trachea—lung cancer	0.00251	0.0145	CbGeAlD
Orlistat—FASN—Afatinib—Gefitinib—lung cancer	0.00217	0.202	CbGdCrCtD
Orlistat—PLA2G4A—bone marrow—lung cancer	0.00199	0.0115	CbGeAlD
Orlistat—PLA2G4A—lung—lung cancer	0.00181	0.0104	CbGeAlD
Orlistat—Ethanolamine Oleate—CYP2E1—lung cancer	0.00158	1	CrCbGaD
Orlistat—PLA2G4A—lymph node—lung cancer	0.00123	0.00711	CbGeAlD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—lung cancer	0.000987	0.092	CbGdCrCtD
Orlistat—FASN—Azacitidine—Gemcitabine—lung cancer	0.000574	0.0534	CbGdCrCtD
Orlistat—Hyperhidrosis—Etoposide—lung cancer	0.000214	0.000583	CcSEcCtD
Orlistat—Feeling abnormal—Gemcitabine—lung cancer	0.000214	0.000582	CcSEcCtD
Orlistat—Dizziness—Vinorelbine—lung cancer	0.000214	0.000581	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—lung cancer	0.000214	0.000581	CcSEcCtD
Orlistat—Nervous system disorder—Paclitaxel—lung cancer	0.000213	0.00058	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—lung cancer	0.000213	0.000579	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—lung cancer	0.000212	0.000575	CcSEcCtD
Orlistat—Skin disorder—Paclitaxel—lung cancer	0.000211	0.000574	CcSEcCtD
Orlistat—Abdominal pain—Irinotecan—lung cancer	0.000211	0.000573	CcSEcCtD
Orlistat—Body temperature increased—Irinotecan—lung cancer	0.000211	0.000573	CcSEcCtD
Orlistat—Decreased appetite—Cisplatin—lung cancer	0.00021	0.000572	CcSEcCtD
Orlistat—Hyperhidrosis—Paclitaxel—lung cancer	0.00021	0.000572	CcSEcCtD
Orlistat—Gastrointestinal disorder—Cisplatin—lung cancer	0.000209	0.000568	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—lung cancer	0.000208	0.000566	CcSEcCtD
Orlistat—Infestation—Methotrexate—lung cancer	0.000208	0.000566	CcSEcCtD
Orlistat—Depression—Methotrexate—lung cancer	0.000208	0.000565	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—lung cancer	0.000207	0.000563	CcSEcCtD
Orlistat—Pain—Cisplatin—lung cancer	0.000207	0.000563	CcSEcCtD
Orlistat—Vomiting—Vinorelbine—lung cancer	0.000206	0.000559	CcSEcCtD
Orlistat—Body temperature increased—Gemcitabine—lung cancer	0.000205	0.000558	CcSEcCtD
Orlistat—Renal failure—Methotrexate—lung cancer	0.000205	0.000557	CcSEcCtD
Orlistat—Rash—Vinorelbine—lung cancer	0.000204	0.000554	CcSEcCtD
Orlistat—Dermatitis—Vinorelbine—lung cancer	0.000204	0.000554	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—lung cancer	0.000204	0.000554	CcSEcCtD
Orlistat—Headache—Vinorelbine—lung cancer	0.000203	0.000551	CcSEcCtD
Orlistat—Influenza—Doxorubicin—lung cancer	0.000202	0.00055	CcSEcCtD
Orlistat—Asthma—Doxorubicin—lung cancer	0.000202	0.00055	CcSEcCtD
Orlistat—Palpitations—Docetaxel—lung cancer	0.0002	0.000543	CcSEcCtD
Orlistat—Feeling abnormal—Cisplatin—lung cancer	0.0002	0.000543	CcSEcCtD
Orlistat—Paraesthesia—Etoposide—lung cancer	0.000199	0.000542	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—lung cancer	0.000198	0.000539	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000198	0.000539	CcSEcCtD
Orlistat—Cough—Docetaxel—lung cancer	0.000197	0.000536	CcSEcCtD
Orlistat—Hepatobiliary disease—Methotrexate—lung cancer	0.000197	0.000536	CcSEcCtD
Orlistat—Insomnia—Paclitaxel—lung cancer	0.000197	0.000535	CcSEcCtD
Orlistat—Hypersensitivity—Irinotecan—lung cancer	0.000196	0.000534	CcSEcCtD
Orlistat—Convulsion—Docetaxel—lung cancer	0.000196	0.000532	CcSEcCtD
Orlistat—Paraesthesia—Paclitaxel—lung cancer	0.000195	0.000531	CcSEcCtD
Orlistat—Decreased appetite—Etoposide—lung cancer	0.000193	0.000524	CcSEcCtD
Orlistat—Chest pain—Docetaxel—lung cancer	0.000192	0.000523	CcSEcCtD
Orlistat—Myalgia—Docetaxel—lung cancer	0.000192	0.000523	CcSEcCtD
Orlistat—Nausea—Vinorelbine—lung cancer	0.000192	0.000522	CcSEcCtD
Orlistat—Gastrointestinal disorder—Etoposide—lung cancer	0.000191	0.000521	CcSEcCtD
Orlistat—Dyspepsia—Paclitaxel—lung cancer	0.000191	0.000521	CcSEcCtD
Orlistat—Body temperature increased—Cisplatin—lung cancer	0.000191	0.00052	CcSEcCtD
Orlistat—Asthenia—Irinotecan—lung cancer	0.000191	0.00052	CcSEcCtD
Orlistat—Fatigue—Etoposide—lung cancer	0.000191	0.00052	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000191	0.000519	CcSEcCtD
Orlistat—Pain—Etoposide—lung cancer	0.00019	0.000516	CcSEcCtD
Orlistat—Decreased appetite—Paclitaxel—lung cancer	0.000189	0.000514	CcSEcCtD
Orlistat—Dry mouth—Docetaxel—lung cancer	0.000188	0.000511	CcSEcCtD
Orlistat—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000188	0.000511	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—lung cancer	0.000188	0.000511	CcSEcCtD
Orlistat—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000188	0.000511	CcSEcCtD
Orlistat—Fatigue—Paclitaxel—lung cancer	0.000187	0.00051	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—lung cancer	0.000187	0.000508	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—lung cancer	0.000187	0.000508	CcSEcCtD
Orlistat—Asthenia—Gemcitabine—lung cancer	0.000186	0.000507	CcSEcCtD
Orlistat—Pain—Paclitaxel—lung cancer	0.000186	0.000506	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—lung cancer	0.000186	0.000505	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—lung cancer	0.000185	0.000502	CcSEcCtD
Orlistat—Anaphylactic shock—Docetaxel—lung cancer	0.000184	0.000501	CcSEcCtD
Orlistat—Oedema—Docetaxel—lung cancer	0.000184	0.000501	CcSEcCtD
Orlistat—Pruritus—Gemcitabine—lung cancer	0.000184	0.0005	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—lung cancer	0.000183	0.000498	CcSEcCtD
Orlistat—Infection—Docetaxel—lung cancer	0.000183	0.000498	CcSEcCtD
Orlistat—Feeling abnormal—Etoposide—lung cancer	0.000183	0.000497	CcSEcCtD
Orlistat—Diarrhoea—Irinotecan—lung cancer	0.000182	0.000496	CcSEcCtD
Orlistat—Gastrointestinal pain—Etoposide—lung cancer	0.000181	0.000493	CcSEcCtD
Orlistat—Nervous system disorder—Docetaxel—lung cancer	0.000181	0.000492	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—lung cancer	0.00018	0.00049	CcSEcCtD
Orlistat—Infestation—Doxorubicin—lung cancer	0.00018	0.00049	CcSEcCtD
Orlistat—Feeling abnormal—Paclitaxel—lung cancer	0.000179	0.000487	CcSEcCtD
Orlistat—Skin disorder—Docetaxel—lung cancer	0.000179	0.000487	CcSEcCtD
Orlistat—Hypersensitivity—Cisplatin—lung cancer	0.000178	0.000485	CcSEcCtD
Orlistat—Gastrointestinal pain—Paclitaxel—lung cancer	0.000178	0.000484	CcSEcCtD
Orlistat—Diarrhoea—Gemcitabine—lung cancer	0.000178	0.000483	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—lung cancer	0.000177	0.000482	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—lung cancer	0.000177	0.000481	CcSEcCtD
Orlistat—Dizziness—Irinotecan—lung cancer	0.000176	0.000479	CcSEcCtD
Orlistat—Urticaria—Etoposide—lung cancer	0.000176	0.000479	CcSEcCtD
Orlistat—Abdominal pain—Etoposide—lung cancer	0.000175	0.000477	CcSEcCtD
Orlistat—Body temperature increased—Etoposide—lung cancer	0.000175	0.000477	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—lung cancer	0.000175	0.000477	CcSEcCtD
Orlistat—Asthenia—Cisplatin—lung cancer	0.000174	0.000472	CcSEcCtD
Orlistat—Urticaria—Paclitaxel—lung cancer	0.000173	0.00047	CcSEcCtD
Orlistat—Abdominal pain—Paclitaxel—lung cancer	0.000172	0.000467	CcSEcCtD
Orlistat—Body temperature increased—Paclitaxel—lung cancer	0.000172	0.000467	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—lung cancer	0.000171	0.000464	CcSEcCtD
Orlistat—Vomiting—Irinotecan—lung cancer	0.00017	0.000461	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—lung cancer	0.000169	0.00046	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—lung cancer	0.000169	0.000459	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—lung cancer	0.000169	0.000458	CcSEcCtD
Orlistat—Rash—Irinotecan—lung cancer	0.000168	0.000457	CcSEcCtD
Orlistat—Dermatitis—Irinotecan—lung cancer	0.000168	0.000457	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000168	0.000457	CcSEcCtD
Orlistat—Headache—Irinotecan—lung cancer	0.000167	0.000454	CcSEcCtD
Orlistat—Insomnia—Docetaxel—lung cancer	0.000167	0.000453	CcSEcCtD
Orlistat—Diarrhoea—Cisplatin—lung cancer	0.000166	0.00045	CcSEcCtD
Orlistat—Paraesthesia—Docetaxel—lung cancer	0.000166	0.00045	CcSEcCtD
Orlistat—Alopecia—Methotrexate—lung cancer	0.000165	0.000449	CcSEcCtD
Orlistat—Vomiting—Gemcitabine—lung cancer	0.000165	0.000449	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—lung cancer	0.000164	0.000445	CcSEcCtD
Orlistat—Rash—Gemcitabine—lung cancer	0.000164	0.000445	CcSEcCtD
Orlistat—Dermatitis—Gemcitabine—lung cancer	0.000164	0.000445	CcSEcCtD
Orlistat—Hypersensitivity—Etoposide—lung cancer	0.000163	0.000444	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—lung cancer	0.000163	0.000443	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—lung cancer	0.000163	0.000443	CcSEcCtD
Orlistat—Headache—Gemcitabine—lung cancer	0.000163	0.000442	CcSEcCtD
Orlistat—Dyspepsia—Docetaxel—lung cancer	0.000162	0.000441	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—lung cancer	0.000162	0.00044	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—lung cancer	0.000162	0.00044	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—lung cancer	0.000161	0.000437	CcSEcCtD
Orlistat—Decreased appetite—Docetaxel—lung cancer	0.00016	0.000436	CcSEcCtD
Orlistat—Hypersensitivity—Paclitaxel—lung cancer	0.00016	0.000436	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—lung cancer	0.00016	0.000435	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—lung cancer	0.00016	0.000434	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—lung cancer	0.000159	0.000433	CcSEcCtD
Orlistat—Gastrointestinal disorder—Docetaxel—lung cancer	0.000159	0.000433	CcSEcCtD
Orlistat—Asthenia—Etoposide—lung cancer	0.000159	0.000433	CcSEcCtD
Orlistat—Fatigue—Docetaxel—lung cancer	0.000159	0.000432	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—lung cancer	0.000159	0.000432	CcSEcCtD
Orlistat—Nausea—Irinotecan—lung cancer	0.000158	0.000431	CcSEcCtD
Orlistat—Pain—Docetaxel—lung cancer	0.000158	0.000429	CcSEcCtD
Orlistat—Back pain—Methotrexate—lung cancer	0.000157	0.000428	CcSEcCtD
Orlistat—Pruritus—Etoposide—lung cancer	0.000157	0.000427	CcSEcCtD
Orlistat—Asthenia—Paclitaxel—lung cancer	0.000156	0.000424	CcSEcCtD
Orlistat—Nausea—Gemcitabine—lung cancer	0.000154	0.00042	CcSEcCtD
Orlistat—Vomiting—Cisplatin—lung cancer	0.000154	0.000419	CcSEcCtD
Orlistat—Pruritus—Paclitaxel—lung cancer	0.000154	0.000418	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—lung cancer	0.000153	0.000417	CcSEcCtD
Orlistat—Rash—Cisplatin—lung cancer	0.000153	0.000415	CcSEcCtD
Orlistat—Dermatitis—Cisplatin—lung cancer	0.000153	0.000415	CcSEcCtD
Orlistat—Feeling abnormal—Docetaxel—lung cancer	0.000152	0.000413	CcSEcCtD
Orlistat—Diarrhoea—Etoposide—lung cancer	0.000152	0.000413	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—lung cancer	0.000151	0.000411	CcSEcCtD
Orlistat—Gastrointestinal pain—Docetaxel—lung cancer	0.000151	0.00041	CcSEcCtD
Orlistat—Diarrhoea—Paclitaxel—lung cancer	0.000149	0.000405	CcSEcCtD
Orlistat—Malaise—Methotrexate—lung cancer	0.000147	0.000399	CcSEcCtD
Orlistat—Dizziness—Etoposide—lung cancer	0.000147	0.000399	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—lung cancer	0.000146	0.000398	CcSEcCtD
Orlistat—Vertigo—Methotrexate—lung cancer	0.000146	0.000398	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—lung cancer	0.000146	0.000397	CcSEcCtD
Orlistat—Abdominal pain—Docetaxel—lung cancer	0.000146	0.000396	CcSEcCtD
Orlistat—Body temperature increased—Docetaxel—lung cancer	0.000146	0.000396	CcSEcCtD
Orlistat—Dizziness—Paclitaxel—lung cancer	0.000144	0.000391	CcSEcCtD
Orlistat—Nausea—Cisplatin—lung cancer	0.000144	0.000391	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—lung cancer	0.000143	0.000389	CcSEcCtD
Orlistat—Cough—Methotrexate—lung cancer	0.000142	0.000386	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—lung cancer	0.000142	0.000386	CcSEcCtD
Orlistat—Convulsion—Methotrexate—lung cancer	0.000141	0.000384	CcSEcCtD
Orlistat—Vomiting—Etoposide—lung cancer	0.000141	0.000383	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—lung cancer	0.000141	0.000383	CcSEcCtD
Orlistat—Rash—Etoposide—lung cancer	0.00014	0.00038	CcSEcCtD
Orlistat—Dermatitis—Etoposide—lung cancer	0.00014	0.00038	CcSEcCtD
Orlistat—Headache—Etoposide—lung cancer	0.000139	0.000378	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—lung cancer	0.000139	0.000378	CcSEcCtD
Orlistat—Myalgia—Methotrexate—lung cancer	0.000139	0.000377	CcSEcCtD
Orlistat—Chest pain—Methotrexate—lung cancer	0.000139	0.000377	CcSEcCtD
Orlistat—Vomiting—Paclitaxel—lung cancer	0.000138	0.000376	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—lung cancer	0.000138	0.000375	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000138	0.000374	CcSEcCtD
Orlistat—Rash—Paclitaxel—lung cancer	0.000137	0.000373	CcSEcCtD
Orlistat—Dermatitis—Paclitaxel—lung cancer	0.000137	0.000373	CcSEcCtD
Orlistat—Discomfort—Methotrexate—lung cancer	0.000137	0.000372	CcSEcCtD
Orlistat—Back pain—Doxorubicin—lung cancer	0.000136	0.000371	CcSEcCtD
Orlistat—Headache—Paclitaxel—lung cancer	0.000136	0.00037	CcSEcCtD
Orlistat—Hypersensitivity—Docetaxel—lung cancer	0.000136	0.000369	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—lung cancer	0.000136	0.000369	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—lung cancer	0.000133	0.000361	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—lung cancer	0.000133	0.000361	CcSEcCtD
Orlistat—Asthenia—Docetaxel—lung cancer	0.000132	0.00036	CcSEcCtD
Orlistat—Infection—Methotrexate—lung cancer	0.000132	0.000359	CcSEcCtD
Orlistat—Nausea—Etoposide—lung cancer	0.000132	0.000358	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—lung cancer	0.000131	0.000356	CcSEcCtD
Orlistat—Pruritus—Docetaxel—lung cancer	0.00013	0.000355	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—lung cancer	0.00013	0.000354	CcSEcCtD
Orlistat—Nausea—Paclitaxel—lung cancer	0.000129	0.000351	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—lung cancer	0.000129	0.000351	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—lung cancer	0.000128	0.000349	CcSEcCtD
Orlistat—Malaise—Doxorubicin—lung cancer	0.000127	0.000346	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—lung cancer	0.000127	0.000344	CcSEcCtD
Orlistat—Diarrhoea—Docetaxel—lung cancer	0.000126	0.000343	CcSEcCtD
Orlistat—Palpitations—Doxorubicin—lung cancer	0.000125	0.000339	CcSEcCtD
Orlistat—Cough—Doxorubicin—lung cancer	0.000123	0.000334	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—lung cancer	0.000122	0.000332	CcSEcCtD
Orlistat—Dizziness—Docetaxel—lung cancer	0.000122	0.000331	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000121	0.000329	CcSEcCtD
Orlistat—Insomnia—Methotrexate—lung cancer	0.00012	0.000327	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—lung cancer	0.00012	0.000326	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—lung cancer	0.00012	0.000326	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—lung cancer	0.00012	0.000325	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—lung cancer	0.000119	0.000324	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000119	0.000324	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—lung cancer	0.000119	0.000322	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—lung cancer	0.000117	0.000319	CcSEcCtD
Orlistat—Vomiting—Docetaxel—lung cancer	0.000117	0.000319	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—lung cancer	0.000117	0.000318	CcSEcCtD
Orlistat—Rash—Docetaxel—lung cancer	0.000116	0.000316	CcSEcCtD
Orlistat—Dermatitis—Docetaxel—lung cancer	0.000116	0.000316	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—lung cancer	0.000115	0.000314	CcSEcCtD
Orlistat—Headache—Docetaxel—lung cancer	0.000115	0.000314	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—lung cancer	0.000115	0.000313	CcSEcCtD
Orlistat—Oedema—Doxorubicin—lung cancer	0.000115	0.000313	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—lung cancer	0.000115	0.000312	CcSEcCtD
Orlistat—Fatigue—Methotrexate—lung cancer	0.000115	0.000311	CcSEcCtD
Orlistat—Infection—Doxorubicin—lung cancer	0.000114	0.000311	CcSEcCtD
Orlistat—Pain—Methotrexate—lung cancer	0.000114	0.000309	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—lung cancer	0.000113	0.000307	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—lung cancer	0.000112	0.000304	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—lung cancer	0.000111	0.000302	CcSEcCtD
Orlistat—Nausea—Docetaxel—lung cancer	0.000109	0.000298	CcSEcCtD
Orlistat—Feeling abnormal—Methotrexate—lung cancer	0.000109	0.000298	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—lung cancer	0.000109	0.000295	CcSEcCtD
Orlistat—Urticaria—Methotrexate—lung cancer	0.000106	0.000287	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—lung cancer	0.000105	0.000286	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—lung cancer	0.000105	0.000286	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000105	0.000285	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—lung cancer	0.000104	0.000283	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—lung cancer	0.000103	0.000281	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—lung cancer	0.000101	0.000275	CcSEcCtD
Orlistat—Decreased appetite—Doxorubicin—lung cancer	0.0001	0.000272	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—lung cancer	9.93e-05	0.00027	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—lung cancer	9.92e-05	0.00027	CcSEcCtD
Orlistat—Pain—Doxorubicin—lung cancer	9.84e-05	0.000268	CcSEcCtD
Orlistat—Hypersensitivity—Methotrexate—lung cancer	9.79e-05	0.000266	CcSEcCtD
Orlistat—Asthenia—Methotrexate—lung cancer	9.53e-05	0.000259	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—lung cancer	9.48e-05	0.000258	CcSEcCtD
Orlistat—Gastrointestinal pain—Doxorubicin—lung cancer	9.41e-05	0.000256	CcSEcCtD
Orlistat—Pruritus—Methotrexate—lung cancer	9.4e-05	0.000256	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—lung cancer	9.14e-05	0.000249	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—lung cancer	9.09e-05	0.000247	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—lung cancer	9.09e-05	0.000247	CcSEcCtD
Orlistat—Diarrhoea—Methotrexate—lung cancer	9.09e-05	0.000247	CcSEcCtD
Orlistat—Dizziness—Methotrexate—lung cancer	8.79e-05	0.000239	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—lung cancer	8.48e-05	0.00023	CcSEcCtD
Orlistat—Vomiting—Methotrexate—lung cancer	8.45e-05	0.00023	CcSEcCtD
Orlistat—Rash—Methotrexate—lung cancer	8.38e-05	0.000228	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—lung cancer	8.37e-05	0.000228	CcSEcCtD
Orlistat—Headache—Methotrexate—lung cancer	8.32e-05	0.000226	CcSEcCtD
Orlistat—Asthenia—Doxorubicin—lung cancer	8.25e-05	0.000224	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—lung cancer	8.14e-05	0.000221	CcSEcCtD
Orlistat—Nausea—Methotrexate—lung cancer	7.89e-05	0.000215	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—lung cancer	7.87e-05	0.000214	CcSEcCtD
Orlistat—Dizziness—Doxorubicin—lung cancer	7.61e-05	0.000207	CcSEcCtD
Orlistat—Vomiting—Doxorubicin—lung cancer	7.31e-05	0.000199	CcSEcCtD
Orlistat—Rash—Doxorubicin—lung cancer	7.25e-05	0.000197	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—lung cancer	7.25e-05	0.000197	CcSEcCtD
Orlistat—Headache—Doxorubicin—lung cancer	7.21e-05	0.000196	CcSEcCtD
Orlistat—Nausea—Doxorubicin—lung cancer	6.83e-05	0.000186	CcSEcCtD
Orlistat—CYP3A4—Metapathway biotransformation—GSTP1—lung cancer	3.73e-05	0.000128	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.72e-05	0.000127	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—lung cancer	3.71e-05	0.000127	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFC—lung cancer	3.71e-05	0.000127	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—lung cancer	3.71e-05	0.000127	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRAS—lung cancer	3.7e-05	0.000127	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRAS—lung cancer	3.7e-05	0.000127	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.68e-05	0.000126	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—lung cancer	3.66e-05	0.000125	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—lung cancer	3.66e-05	0.000125	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RAF1—lung cancer	3.65e-05	0.000125	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CB—lung cancer	3.56e-05	0.000122	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—lung cancer	3.56e-05	0.000122	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—JUN—lung cancer	3.56e-05	0.000122	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK3—lung cancer	3.55e-05	0.000121	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK3—lung cancer	3.55e-05	0.000121	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADCY1—lung cancer	3.51e-05	0.00012	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1A—lung cancer	3.48e-05	0.000119	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTM1—lung cancer	3.48e-05	0.000119	CbGpPWpGaD
Orlistat—FASN—Disease—PTEN—lung cancer	3.48e-05	0.000119	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—lung cancer	3.46e-05	0.000119	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—lung cancer	3.46e-05	0.000118	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—lung cancer	3.45e-05	0.000118	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—lung cancer	3.45e-05	0.000118	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1A—lung cancer	3.45e-05	0.000118	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—lung cancer	3.44e-05	0.000118	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTEN—lung cancer	3.44e-05	0.000118	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	3.43e-05	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PPP2R1B—lung cancer	3.42e-05	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SMARCA4—lung cancer	3.42e-05	0.000117	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—lung cancer	3.37e-05	0.000115	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—lung cancer	3.37e-05	0.000115	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CB—lung cancer	3.37e-05	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP2E1—lung cancer	3.35e-05	0.000115	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—lung cancer	3.34e-05	0.000114	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NQO1—lung cancer	3.31e-05	0.000113	CbGpPWpGaD
Orlistat—FASN—Disease—EP300—lung cancer	3.31e-05	0.000113	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP1A1—lung cancer	3.3e-05	0.000113	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HSPB1—lung cancer	3.3e-05	0.000113	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EP300—lung cancer	3.28e-05	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—lung cancer	3.27e-05	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTHLH—lung cancer	3.26e-05	0.000112	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	3.25e-05	0.000111	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.25e-05	0.000111	CbGpPWpGaD
Orlistat—FASN—Disease—SRC—lung cancer	3.22e-05	0.00011	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.22e-05	0.00011	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—lung cancer	3.21e-05	0.00011	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SRC—lung cancer	3.19e-05	0.000109	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—lung cancer	3.19e-05	0.000109	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—lung cancer	3.19e-05	0.000109	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—lung cancer	3.11e-05	0.000106	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—lung cancer	3.11e-05	0.000106	CbGpPWpGaD
Orlistat—FASN—Disease—NRAS—lung cancer	3.1e-05	0.000106	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—lung cancer	3.08e-05	0.000105	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRAS—lung cancer	3.07e-05	0.000105	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—lung cancer	3.07e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ANXA1—lung cancer	3.06e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—STK11—lung cancer	2.99e-05	0.000102	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK3—lung cancer	2.97e-05	0.000102	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FLT1—lung cancer	2.97e-05	0.000102	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK3—lung cancer	2.94e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—EP300—lung cancer	2.94e-05	0.000101	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—lung cancer	2.93e-05	0.0001	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—lung cancer	2.93e-05	0.0001	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—lung cancer	2.91e-05	9.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APP—lung cancer	2.9e-05	9.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH3—lung cancer	2.9e-05	9.94e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—lung cancer	2.9e-05	9.93e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—COL4A3BP—lung cancer	2.9e-05	9.93e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AZIN2—lung cancer	2.9e-05	9.93e-05	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—lung cancer	2.89e-05	9.88e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF9—lung cancer	2.88e-05	9.86e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—lung cancer	2.86e-05	9.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SRC—lung cancer	2.86e-05	9.78e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—lung cancer	2.83e-05	9.69e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—lung cancer	2.83e-05	9.69e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—lung cancer	2.83e-05	9.69e-05	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—lung cancer	2.82e-05	9.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.8e-05	9.6e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—lung cancer	2.8e-05	9.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—lung cancer	2.78e-05	9.52e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—EP300—lung cancer	2.78e-05	9.5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTP1—lung cancer	2.76e-05	9.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUNB—lung cancer	2.75e-05	9.41e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NRAS—lung cancer	2.75e-05	9.4e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—lung cancer	2.71e-05	9.27e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—lung cancer	2.71e-05	9.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAT—lung cancer	2.69e-05	9.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.67e-05	9.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CG—lung cancer	2.67e-05	9.14e-05	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—lung cancer	2.67e-05	9.13e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—lung cancer	2.64e-05	9.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK3—lung cancer	2.63e-05	9.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCB1—lung cancer	2.62e-05	8.95e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—lung cancer	2.59e-05	8.87e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—lung cancer	2.59e-05	8.87e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMS—lung cancer	2.57e-05	8.79e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—POMC—lung cancer	2.54e-05	8.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—lung cancer	2.54e-05	8.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STK11—lung cancer	2.5e-05	8.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6R—lung cancer	2.48e-05	8.48e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ATP5H—lung cancer	2.47e-05	8.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—POMC—lung cancer	2.46e-05	8.41e-05	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—lung cancer	2.45e-05	8.39e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—lung cancer	2.43e-05	8.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FOXO3—lung cancer	2.41e-05	8.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1A1—lung cancer	2.41e-05	8.24e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—lung cancer	2.39e-05	8.19e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—lung cancer	2.39e-05	8.19e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ERCC2—lung cancer	2.39e-05	8.17e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—lung cancer	2.37e-05	8.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—lung cancer	2.37e-05	8.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAP2K1—lung cancer	2.36e-05	8.08e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—lung cancer	2.35e-05	8.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CD—lung cancer	2.35e-05	8.03e-05	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—lung cancer	2.27e-05	7.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AVP—lung cancer	2.26e-05	7.73e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—lung cancer	2.24e-05	7.68e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLBD1—lung cancer	2.2e-05	7.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1R—lung cancer	2.17e-05	7.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—lung cancer	2.17e-05	7.44e-05	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—lung cancer	2.17e-05	7.43e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—lung cancer	2.15e-05	7.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HES1—lung cancer	2.14e-05	7.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—lung cancer	2.1e-05	7.19e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RAF1—lung cancer	2.1e-05	7.17e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOA1—lung cancer	2.07e-05	7.07e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—lung cancer	2.05e-05	7.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CB—lung cancer	2.05e-05	7e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD17B10—lung cancer	2.01e-05	6.88e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—lung cancer	2.01e-05	6.88e-05	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—lung cancer	2e-05	6.85e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—lung cancer	1.98e-05	6.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.98e-05	6.77e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—lung cancer	1.97e-05	6.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB3—lung cancer	1.95e-05	6.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CG—lung cancer	1.89e-05	6.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—lung cancer	1.88e-05	6.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—lung cancer	1.87e-05	6.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CKB—lung cancer	1.87e-05	6.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR1—lung cancer	1.82e-05	6.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—POMC—lung cancer	1.8e-05	6.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIF1A—lung cancer	1.79e-05	6.13e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—lung cancer	1.78e-05	6.07e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CNDP2—lung cancer	1.76e-05	6.01e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM2—lung cancer	1.76e-05	6.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CREBBP—lung cancer	1.75e-05	5.98e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOA1—lung cancer	1.73e-05	5.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—lung cancer	1.71e-05	5.86e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTMR3—lung cancer	1.71e-05	5.85e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—lung cancer	1.68e-05	5.74e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PGAM1—lung cancer	1.67e-05	5.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CD—lung cancer	1.66e-05	5.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—lung cancer	1.64e-05	5.6e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2A7—lung cancer	1.59e-05	5.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APC—lung cancer	1.58e-05	5.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CG—lung cancer	1.58e-05	5.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KIT—lung cancer	1.58e-05	5.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NRAS—lung cancer	1.58e-05	5.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGF—lung cancer	1.56e-05	5.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SDC4—lung cancer	1.56e-05	5.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK3—lung cancer	1.51e-05	5.17e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—POMC—lung cancer	1.5e-05	5.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—lung cancer	1.48e-05	5.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6R—lung cancer	1.46e-05	5.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CREBBP—lung cancer	1.46e-05	5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CB—lung cancer	1.45e-05	4.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—lung cancer	1.44e-05	4.92e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—lung cancer	1.43e-05	4.9e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA3—lung cancer	1.42e-05	4.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RRM1—lung cancer	1.42e-05	4.85e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAP2K1—lung cancer	1.4e-05	4.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CD—lung cancer	1.39e-05	4.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—lung cancer	1.36e-05	4.65e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—B4GALT5—lung cancer	1.33e-05	4.56e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA4—lung cancer	1.3e-05	4.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA2—lung cancer	1.26e-05	4.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—lung cancer	1.25e-05	4.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—lung cancer	1.25e-05	4.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MDM2—lung cancer	1.24e-05	4.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RAF1—lung cancer	1.24e-05	4.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—lung cancer	1.22e-05	4.19e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA1—lung cancer	1.22e-05	4.17e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTOR—lung cancer	1.21e-05	4.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CB—lung cancer	1.21e-05	4.14e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCC3—lung cancer	1.2e-05	4.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—EP300—lung cancer	1.19e-05	4.08e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKR1C1—lung cancer	1.17e-05	3.99e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—lung cancer	1.16e-05	3.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—lung cancer	1.15e-05	3.95e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UGT1A1—lung cancer	1.13e-05	3.88e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—lung cancer	1.11e-05	3.8e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—lung cancer	1.11e-05	3.8e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—lung cancer	1.1e-05	3.78e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNG11—lung cancer	1.09e-05	3.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—lung cancer	1.08e-05	3.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUN—lung cancer	1.08e-05	3.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—lung cancer	1.05e-05	3.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1A—lung cancer	1.05e-05	3.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—lung cancer	1.04e-05	3.57e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDOA—lung cancer	1.04e-05	3.56e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—lung cancer	1.02e-05	3.49e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOA3—lung cancer	1.01e-05	3.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EP300—lung cancer	9.96e-06	3.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADCY1—lung cancer	9.82e-06	3.36e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCG2—lung cancer	9.82e-06	3.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SRC—lung cancer	9.68e-06	3.31e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO2—lung cancer	9.63e-06	3.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HPGDS—lung cancer	9.63e-06	3.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPP2R1B—lung cancer	9.57e-06	3.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—lung cancer	9.43e-06	3.23e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTT1—lung cancer	9.34e-06	3.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—lung cancer	9.34e-06	3.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRAS—lung cancer	9.32e-06	3.19e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GCLC—lung cancer	9.23e-06	3.16e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2A6—lung cancer	9.23e-06	3.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK3—lung cancer	8.92e-06	3.05e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—lung cancer	8.81e-06	3.01e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO1—lung cancer	8.75e-06	2.99e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—lung cancer	8.68e-06	2.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—lung cancer	8.49e-06	2.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—lung cancer	8.02e-06	2.74e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2E1—lung cancer	7.85e-06	2.69e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NQO1—lung cancer	7.76e-06	2.66e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—lung cancer	7.37e-06	2.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—lung cancer	7.2e-06	2.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—lung cancer	7.13e-06	2.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—STK11—lung cancer	7e-06	2.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—lung cancer	6.82e-06	2.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—lung cancer	6.52e-06	2.23e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTP1—lung cancer	6.47e-06	2.22e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAT—lung cancer	6.3e-06	2.16e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCB1—lung cancer	6.13e-06	2.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMS—lung cancer	6.02e-06	2.06e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—lung cancer	6.02e-06	2.06e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—lung cancer	5.95e-06	2.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1A1—lung cancer	5.64e-06	1.93e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ERCC2—lung cancer	5.59e-06	1.91e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOA1—lung cancer	4.84e-06	1.66e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CG—lung cancer	4.42e-06	1.51e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—POMC—lung cancer	4.2e-06	1.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CREBBP—lung cancer	4.1e-06	1.4e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CD—lung cancer	3.88e-06	1.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—lung cancer	3.83e-06	1.31e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CB—lung cancer	3.38e-06	1.16e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—lung cancer	3.35e-06	1.15e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—lung cancer	2.92e-06	1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—EP300—lung cancer	2.79e-06	9.55e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—lung cancer	2.06e-06	7.06e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—lung cancer	1.69e-06	5.77e-06	CbGpPWpGaD
